Uloric, Adenuric(febuxostat)
Adenuric, Febuxostat, Uloric (febuxostat) is a small molecule pharmaceutical. Febuxostat was first approved as Adenuric on 2008-04-21. It is used to treat gout in the USA. It has been approved in Europe to treat gout, gouty arthritis, and hyperuricemia. The pharmaceutical is active against xanthine dehydrogenase/oxidase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Febuxostat, Uloric (discontinued: Febuxostat)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| febuxostat | ANDA | 2025-01-10 |
| uloric | New Drug Application | 2023-04-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| gout | EFO_0004274 | D006073 | M10 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
104 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gout | D006073 | EFO_0004274 | M10 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | 1 | 1 | 1 | — | — | 2 |
| Tumor lysis syndrome | D015275 | — | E88.3 | 1 | 1 | 1 | — | — | 2 |
| Hematologic neoplasms | D019337 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Febuxostat |
| INN | febuxostat |
| Description | Febuxostat is a 1,3-thiazolemonocarboxylic acid that is 4-methyl-1,3-thiazole-5-carboxylic acid which is substituted by a 3-cyano-4-(2-methylpropoxy)phenyl group at position 2. It is an orally-active, potent, and selective xanthine oxidase inhibitor used for the treatment of chronic hyperuricaemia in patients with gout. It has a role as an EC 1.17.3.2 (xanthine oxidase) inhibitor. It is an aromatic ether, a nitrile and a 1,3-thiazolemonocarboxylic acid. |
| Classification | Small molecule |
| Drug class | enzyme inhibitors: xanthine oxidase/dehydrogenase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 144060-53-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1164729 |
| ChEBI ID | — |
| PubChem CID | 134018 |
| DrugBank | DB04854 |
| UNII ID | 101V0R1N2E (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Febuxostat
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,351 documents
View more details
Safety
Black-box Warning
Black-box warning for: Febuxostat, Uloric
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,720 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use